蘭花科創(600123.SH):所屬部分化肥化工企業停產
格隆匯4月1日丨蘭花科創(600123.SH)公佈,鑑於公司所屬陽化分公司規模小、設備老化、工藝落後,成本高、效益差,同時蘭花清潔能源公司主要產品二甲醚市場低迷,價格明顯下降,綜合考慮安全環保和市場因素,公司決定陽化分公司、蘭花清潔能源公司4月1日起繼續停產。新材料分公司因進行年度大修並進行己內酰胺“10改14”節能增效技改項目碰口,將從4月初停產,復產時間另行公告。
以上三家企業2019年1-9月實現營業收入為16.44億元,佔公司合併報表營業收入比例為26.68%,合計虧損8578萬元(以上數據未經審計)。請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.